Ipilimumab Versus Placebo After <br />Complete Resection of Stage III Melanoma: <br />Initial Efficacy and Safety Results from the EORTC 18071 Phase III Trial

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 2

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 3

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Immune Checkpoint Inhibitor Ipilimumab

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

EORTC 18071/CA184-029: Study Design

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Key Eligibility Criteria

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 7

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Baseline Patient Characteristics

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Primary Endpoint: Recurrence-free Survival (IRC)

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Recurrence-free Survival: Prespecified Subgroups

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 11

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 12

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Time to Onset of Grade 2-5 irAEs

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 14

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 15

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Subgroup Analyses of RFS: Microscopic (N1) vs Clinically Palpable (N2) Lymph Nodes

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Summary/Conclusions

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Acknowledgments

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting